US · Healthcare · Medical Devices
EPS came in at 2.07 against a street estimate of 2.01 — a beat of 3.0%.
Analysts rate Zimmer Biomet Holdings Inc a hold (11 buy, 16 hold, 2 sell out of 29) with an average price target of $107.57.
CONFIDENT ZBH beat Q2 estimates on 4.8% reported growth, raised full-year guidance, and delivered strong hip and robotics momentum. U.S. sales force transformation tracking ahead of plan. Company raised FY26 organic guidance to 2.25–3.25% and EPS to $8.47–$8.59. Q2 2026 U.S. outperforming on sales force transformation execution. International pressured by China (-20% YoY), geopolitical events, tenders; company pegging overall market at 4–5% growth. Analysts pressed on market slowdown, China/Medicaid risks, and competitive hip acceleration. Management dismissed macro concerns citing data on waiting lists, referral cycles, cancellation rates; attributed outperformance to sales execution and product innovation, not market share gains. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Dodge & Cox | 12.65% |
| BlackRock Inc | 8.04% |
| Vanguard Capital Management, LLC | 6.71% |
| Harris Associates L.P. | 6.68% |
| Capital Research & Mgmt Co - Division 3 | 6.39% |
| State Street Corp | 4.63% |
| Vanguard Portfolio Management, LLC | 4.54% |
| T. Rowe Price Associates, Inc. | 4.19% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 ZIMMER BIOMET HOLDINGS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Executive Departure: Kevin Thornal, Group President of Global Businesses and the Ameri | 2026-09-08 |
| Quarterly report · Q2 2026 ZIMMER BIOMET HOLDINGS, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net Sales (Six Months): $4,263.7 million, up 7. | 2026-08-05 |
| Company announcement · Q3 2026 ZIMMER BIOMET HOLDINGS, INC. - 8-K SUMMARY HEADLINE NUMBERS • This is a recast filing, not new financial results—the company is reorganizing how it | 2026-08-05 |
| Results announced · Q3 2026 ZIMMER BIOMET HOLDINGS, INC. - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 net sales: $2,177.0 million, up 4.8% reported / 4.7% constant cur | 2026-08-05 |
| Material agreement · Q2 2026 ZIMMER BIOMET HOLDINGS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company entered into two new credit facilities on June 26, 2026, totaling $2.75 billio | 2026-06-29 |
| Quarterly report · Q1 2026 ZIMMER BIOMET HOLDINGS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Net Sales: $2,086.7 million (Q1 2026) vs. $1,909.1 million (Q1 2025) = +9.3% | 2026-05-01 |
| Proxy statement · Q2 2026 ZIMMER BIOMET HOLDINGS, INC. – PROXY STATEMENT SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect 10 directors to serve until the 2027 | 2026-04-01 |
| Annual report FY2025 ZIMMER BIOMET HOLDINGS, INC. – 10-K SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Public company: Zimmer Biomet Holdings, Inc.; Delaware inco | 2026-02-20 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.24 / share ex-date Sep 30, 2026 · pay Oct 30, 2026 | 2026-09-30 |
| Dividend | $0.24 / share ex-date Jun 25, 2026 · pay Jul 31, 2026 | 2026-06-25 |
| Dividend | $0.24 / share ex-date Mar 31, 2026 · pay Apr 30, 2026 | 2026-03-31 |
| Dividend | $0.24 / share ex-date Dec 30, 2025 · pay Jan 30, 2026 | 2025-12-30 |
| Dividend | $0.24 / share ex-date Sep 30, 2025 · pay Oct 31, 2025 | 2025-09-30 |
| Announcement | Date |
|---|---|
| Second quarter results with raised full-year 2026 revenue and EPS guidance Zimmer Biomet, a major medical device company, reported strong second quarter 2026 results with net sales of $2.177 billion, up 4.8% year-over-year (4.0% organic growth excluding acquisition | 2026-08-05 |
| Increases share repurchase expectations to $1 billion by year end Zimmer Biomet announced it will increase share repurchases by $250 million to a total of $1 billion during fiscal year 2026, using its existing $1.5 billion authorization approved in Februar | 2026-05-12 |
| Q1 2026 results; raises adjusted EPS and free cash flow guidance Zimmer Biomet, a major medical device company, reported strong Q1 2026 results with net sales of $2.087 billion, up 9.3% year-over-year (6.8% adjusted for currency). Diluted earnings per sha | 2026-04-28 |
| Full-year 2026 financial guidance provided; $1.5B buyback authorization approved Zimmer Biomet, a major medical device company, reported 2025 results with mixed signals. Fourth quarter net sales reached $2.244 billion, up 10.9% reported but only 5.4% on organic basis (ex | 2026-02-10 |
| Q3 2025 results reported; full-year 2025 guidance narrowed and maintained Zimmer Biomet, a major orthopedic medical device company, reported strong third quarter 2025 results. Net sales reached $2.001 billion, up 9.7% year-over-year (8.6% adjusting for currency ef | 2025-11-05 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Zimmer Biomet Holdings Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.